Ignite Creation Date:
2025-12-25 @ 1:10 AM
Ignite Modification Date:
2026-05-20 @ 3:59 AM
Study NCT ID:
NCT00358293
Status:
COMPLETED
Last Update Posted:
2009-01-21
First Post:
2006-07-27
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Study of Nighttime Dosing of Sublingual Tizanidine (12 mg) in Multiple Sclerosis (MS) Patients With Significant Spasticity
Sponsor:
Teva GTC
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Muscle Spasticity | View |